CASI Pharmaceuticals Inc (CASI) Stock Rating Reaffirmed by Maxim Group
CASI Pharmaceuticals Inc (NASDAQ:CASI)‘s stock had its “buy” rating restated by equities research analysts at Maxim Group in a report released on Wednesday. They currently have a $4.00 target price on the stock. Maxim Group’s price objective indicates a potential upside of 280.95% from the stock’s previous close.
Shares of CASI Pharmaceuticals (NASDAQ:CASI) traded down 1.87% during midday trading on Wednesday, hitting $1.05. 2,168 shares of the stock traded hands. The company’s 50-day moving average is $1.11 and its 200 day moving average is $1.18. CASI Pharmaceuticals has a 52 week low of $0.58 and a 52 week high of $1.82. The firm’s market capitalization is $51.93 million.
CASI Pharmaceuticals (NASDAQ:CASI) last issued its quarterly earnings data on Monday, August 15th. The company reported ($0.08) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.04) by $0.04. Analysts anticipate that CASI Pharmaceuticals will post ($0.16) earnings per share for the current year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/casi-pharmaceuticals-inc-casi-stock-rating-reaffirmed-by-maxim-group.html
In related news, major shareholder Byte Ltd Sparkle acquired 3,753,855 shares of the stock in a transaction that occurred on Friday, June 24th. The shares were bought at an average price of $1.19 per share, for a total transaction of $4,467,087.45. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.
Receive News & Ratings for CASI Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.